T 0921/17 (Bispecific antibody/CHUGAI) of 24.03.2022
- European Case Law Identifier
- ECLI:EP:BA:2022:T092117.20220324
- Date of decision
- 24 March 2022
- Case number
- T 0921/17
- Petition for review of
- -
- Application number
- 06730769.4
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Antibody substituting for function of blood coagulation factor VIII
- Applicant name
- Chugai Seiyaku Kabushiki Kaisha
- Opponent name
- Novo Nordisk A/S
Baxalta Innovations GmbH - Board
- 3.3.04
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(a)European Patent Convention Art 100(b)European Patent Convention Art 100(c)European Patent Convention Art 111(1)European Patent Convention Art 54(3)Rules of procedure of the Boards of Appeal 2020 Art 011Rules of procedure of the Boards of Appeal 2020 Art 013(2)
- Keywords
- Amendments - added subject-matter
Amendments - main request (no)
Late-filed evidence - admitted (no)
Novelty - main request (yes)
Late-filed argument - admitted (no)
Sufficiency of disclosure - main request
Sufficiency of disclosure - claim 3 (yes) - Catchword
- -
- Cited cases
- -
- Citing cases
- -
Order
For these reasons it is decided that:
1. The decision under appeal is set aside.
2. The case is remitted to the opposition division for further prosecution.